CLOs on the Move

Nicka and Associates

www.nicka-associates.com

 
Nicka & Associates, Inc is a Plano, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Broadlane

The Broadlane Group is a leading end-to-end cost management partner for healthcare providers, with product offerings grouped into six service lines that allow healthcare providers to maximize cost efficiencies and invest in the delivery of quality patient care.

Edward Hospital and Health Services Corporation

Edward Hospital & Health Services is a full-service, regional health care organization, offering access to a wide variety of complex medical specialties and innovative programming.

Nebraska Heart Institute

Nebraska Heart Institute is a Lincoln, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Reach Fitness Club

Reach Fitness Club is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

ContraVir Pharmaceuticals, Inc

ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.